SCHEMBL14956928

SCHEMBL14956928

COC(=O)c1ccc(C(=O)OC)c(N)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 5/20 0.47
GAA P10253 4/20 0.47
HSD17B10 Q99714 3/20 0.47
HPGD P15428 3/20 0.47
GLA P06280 2/20 0.47
MAPT P10636 2/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
ATM Q13315 1/20 0.47
CFTR P13569 2/20 0.47
ABL1 P00519 1/20 0.46
MAPK1 P28482 1/20 0.44
NQO2 P16083 4/20 0.43
TSHR P16473 3/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
PDK2 Q15119 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27907009 0.89 KDM4E (0.44) ALDH1A1KDM4EGAAHSD17B10HPGD
SCHEMBL14967079 0.89 ALDH1A1 (0.45) ALDH1A1KDM4EGAAHSD17B10HPGD
SCHEMBL13853239 0.87 CYP1A2 (0.54) ALDH1A1KDM4EHSD17B10MAPTMAPK1
SCHEMBL27486965 0.87 KDM4E (0.41) ALDH1A1KDM4EGAAHSD17B10HPGD
SCHEMBL5264558 0.86 CYP1A2 (0.53) ALDH1A1KDM4EGAAHSD17B10HPGD
SCHEMBL20306004 0.83 ALDH1A1 (0.49) ALDH1A1KDM4EGAAHSD17B10HPGD
SCHEMBL5554420 0.83 MAPK1 (0.46) ALDH1A1KDM4EGAAHSD17B10HPGD
SCHEMBL27459666 0.82 ALDH1A1 (0.49) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL31354558 0.81 LCK (0.46) ALDH1A1GAAHSD17B10MAPTCFTR
SCHEMBL1266209 0.81 KDM4E (0.54) ALDH1A1KDM4EGAAHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023858-B2 Substituted pyrido[2,3-d]pyrimidines as delta-5-desaturase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-05 US disclosed
EP-2597095-A1 FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Takeda Pharmaceutical Company Limited (JP) 2013-05-29 EP disclosed
US-20130131050-A1 FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-23 US disclosed
CN-103119043-A Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL 2013-05-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131050-A1 FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF LTB4R2, LTB4R, LTC4S ALDH1A1 633/4885KDM4E 3749/4885GAA 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.